Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study

Further Publications Rheumatology

Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort study

Arthritis Rheumatol

Hoisnard L, Meyer A, Dray-Spira R, Weill A, Zureik M, Sbidian E

doi: 10.1002/art.42862

Rheumatoid Arthritis

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Lancet Rheumatol

Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, Galloway JB

doi: 10.1016/S2665-9913(24)00221-2

Psoriatic ArthritisRheumatoid Arthritis

The effect of biological treatment on female fertility: A cohort study of women with rheumatoid arthritis and psoriatic arthritis

Semin Arthritis Rheum

Herzberger EH, Hornik-Lurie T, Levi Y, Miller N, Wiser A, Hershko-Klement A

doi: 10.1016/j.semarthrit.2024.152608

Psoriatic ArthritisRheumatoid Arthritis

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Ann Rheum Dis

Hernández-Cruz B, Otero-Varela L, Freire-González M, Busquets-Pérez N, García González AJ, Moreno-Ramos M, Blanco-Madrigal JM, Manrique-Arija S, Perez-Pampin E, Ruiz-Montesino D, Sánchez-Alonso F, Sanchez-Piedra C, Castrejón I, BIOBADASER Study Group

doi: 10.1136/ard-2023-225271

Rheumatoid Arthritis

Preferences for tapering biologic disease-modifying antirheumatic drugs among people with rheumatoid arthritis - a discrete choice experiment

Arthritis Care Res (Hoboken)

Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA

doi: 10.1002/acr.25437

Rheumatoid Arthritis

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Semin Arthritis Rheum

Zhang Q, McDermott GC, Juge PA, Chang SH, Vanni KM, Qian G, Bade KJ, Mueller KT, Kowalski EN, Saavedra AA, Sparks JA

doi: 10.1016/j.semarthrit.2024.152561

Rheumatoid Arthritis

Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study

J Rheumatol

Edwards CJ, Krönke G, Avouac J, Li Z, Conti F, Balsa A, Mo D, Haladyj E, Fischer P, Tanaka M, Takita Y, Hagimori K, Takeuchi T

doi: 10.3899/jrheum.2024-0906

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Psoriatic Arthritis

Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study

Arthritis Res Ther

Currado D, Saracino F, Ruscitti P, Marino A, Pantano I, Vomero M, Berardicurti O, Pavlych V, Di Vico C, Caso F, Costa L, Tasso M, Camarda F, Misceo F, De Vincenzo F, Corrado A, Arcarese L, Rigon A, Vadacca M, Corberi E, Kun L, Trunfio F, Pilato A, Lamberti L, Cantatore FP, Perosa F, Guggino G, Scarpa R, Cipriani P, Ciccia F, Giacomelli R, Navarini L

doi: 10.1186/s13075-024-03396-5

Related content

Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort study

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

The effect of biological treatment on female fertility: A cohort study of women with rheumatoid arthritis and psoriatic arthritis

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Preferences for tapering biologic disease-modifying antirheumatic drugs among people with rheumatoid arthritis - a discrete choice experiment

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study